POPULARITY
Assistant Editor Sam Griffiths is joined by Professor Geoff Manley (UCSF, CA, USA) to discuss his new NIH-NINDS classification of acute TBI, the limitations of traditional classifications, how the new framework was developed, and what it means for the future of TBI research and patient care.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00154-1/fulltext?dgcid=buzzsprout_icw_podcast_May_25_laneurContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Dr. Jeff Lambe talks about progressive multiple sclerosis. Show references: https://journals.lww.com/co-neurology/abstract/2025/06000/re_defining_progression_in_multiple_sclerosis.4.aspx https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00281-8/abstract https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(14)70256-X/abstract https://www.tandfonline.com/doi/full/10.1080/14737175.2022.2143265 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0288967 https://jamanetwork.com/journals/jamaneurology/article-abstract/2809772 https://www.nejm.org/doi/full/10.1056/NEJMoa2415988
Dr. Justin Abbatemarco discuss autoimmune encephalitis with a focus on outcomes. Show reference: https://www.neurology.org/doi/10.1212/WNL.0000000000210109 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00463-5/abstract
Dr. Justin Abbatemarco discusses autoimmune encephalitis with a focus on outcomes. Show references: https://www.neurology.org/doi/10.1212/WNL.0000000000210109 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00463-5/abstract
Increasing numbers of people are surviving stroke but with motor impairments that can contribute substantially to long-term disability. Transcranial direct current stimulation has shown promise in reducing motor impairment when combined with rehabilitation therapy. Sarah Passey talks to Wayne Feng (Duke University School of Medicine, Durham, NC, USA) about his latest trial, TRANSPORT2, which assesses transcranial direct current stimulation in combination with modified constraint-induced movement therapy.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(25)00044-4/fulltext?dgcid=buzzsprout_tlv_podcast_16-04-25_laneurContinue this conversation on social!Follow us today at...https://thelancet.bsky.social/https://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Sarah Passey (The Lancet Neurology) is joined by Michael Tymianski (University Health Network, Toronto, Canada) to discuss an Article in the March issue reporting a meta-analysis looking at neuroprotection in stroke and what can be learnt for future research.Read the full article:https://www.thelancet.com/journals/laneur/article/PiiS1474-4422(24)00515-5/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In this podcast, linked to the February 2025 issue of The Lancet Neurology, Elena Becker-Barroso (Editor-in-Chief) chats to Elizabeth Finger (Western University, London, ON, Canada) about the FOXY trial of oxytocin for apathy in people with frontotemporal dementia.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00456-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Being a teenager is hard. So, imagine for a moment that in addition to everything else that teenagers have to endure, you're a teenager who's been diagnosed with MS. Your ability to participate in after-school activities or just hang out with your friends is impacted by MS-related fatigue. The typical adolescent anxiety over something someone posted on social media evolves into depression. And cognitive issues begin to make it harder for you in the classroom. This is an unfortunate reality for many adolescents who are living with MS. Joining me to discuss how MS affects adolescents and how families can help manage MS is Dr. Ann Yeh. Dr. Yeh is a Professor of Pediatric Neurology at the University of Toronto and the director of the MS and Neuroinflammatory Disorders Program and Fellowship Program at the University of Toronto's Hospital for Sick Children, known as SickKids. We'll also tell you about a new online resource for MS care partners. We'll share the results of a study that explored how different symptom management responsibilities impact MS care partners. We'll share details of a study that demonstrated positive results in improving MS-related fatigue. We'll tell you about the discovery of a plant-based molecule that is showing promise in promoting myelin repair. And we're sharing surprising research results that have more than doubled the prevalence of MS in Australia. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Managing Teenage MS :22 November is National Family Caregivers Month 1:47 You're invited to preview MS Care Partner Connection 3:40 A study reveals the most challenging MS symptoms for care partners to manage 6:33 Study results show Modafinil and cognitive behavioral therapy are both effective in managing MS fatigue 7:25 Researchers discover a plant-based molecule that may be effective in promoting myelin repair 9:46 Prevalence of MS in Australia more than doubled over an 11-year period 12:54 Dr. Ann Yeh discusses the challenges of MS among adolescents 16:05 Share this episode 31:15 Have you downloaded the free RealTalk MS app? 31:36 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/375 ADD YOUR VOICE TO THE CONVERSATION I've always considered the RealTalk MS podcast a conversation. This is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com The MS Care Partner Connection https://mscarepartnerconnection.com Addressing the Needs of Multiple Sclerosis Caregivers from Diagnosis Onward: The Development of a Comprehensive Online Caregiver Protocol https://meridian.allenpress.com/ijmsc/article/25/6/273/496788/Addressing-the-Needs-of-Multiple-Sclerosis STUDY: Symptom Management Among Multiple Sclerosis Care Partners in Canada https://meridian.allenpress.com/ijmsc/article/25/6/281/496792/Symptom-Management-Among-Multiple-Sclerosis-Care STUDY: Comparative Effectiveness of Cognitive Behavioural Therapy, Modafinil, and Their Combination for Treating Fatigue in Multiple Sclerosis (COMBO-MS): A Randomised, Statistician-Blinded, Parallel-Arm Trial https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00354-5/abstract STUDY: Distinct Chemical Structures Inhibit the CEMIP Hyaluronidase and Promote Oligodendrocyte Progenitor Cell Maturationhttps://www.jbc.org/article/S0021-9258(24)02418-9/fulltext STUDY: Significantly Increasing Multiple Sclerosis Prevalence in Australia from 2010 to 2021 https://journals.sagepub.com/doi/10.1177/13524585241265890 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 375 Guest: Dr. Ann Yeh Privacy Policy
Dr. Farrah Mateen and Dr. Katrin Seeher discuss the significant global burden of neurologic conditions, which affects over 3.4 billion people worldwide, and the strategies the WHO is implementing to improve care and awareness. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00038-3/fulltext#seccestitle10
Prof Jorge Correale and Dr Lilyana Amezcua talk to The Lancet Neurology about their Personal View papers, published in the October 2024 issue, on the differential diagnosis of multiple sclerosis in regions outside North America and Western Europe and in people from minority ethnic or racial backgrounds in North America, northern Europe, and Australasia.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00256-4/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Dr. David Perez and Dr. Glenn Nielsen discuss the effectiveness of physiotherapy in treating functional motor disorder and to determine the best approach for physiotherapy treatment. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00135-2/fulltext
Dr Alex Iranzo joins The Lancet Neurology to discuss his recent Review on the association between sleep disorders and Parkinson's disease. The Review is published in the August issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00170-4?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
In the final episode of this two-part series, Dr. Joe Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Ravulizumab + zilucoplan. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00077-7/abstract
In the first episode of a two-part series, Dr. Joseph Conway will discuss four biologic therapies that have been approved in recent years by the FDA for the treatment of adults with generalized myasthenia gravis. In this episode, he will talk about two of the treatment medications: Efgartigimod and Rozanolixizumab. Show references: https://doi.org/10.1016/s1474-4422(21)00159-9 https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00077-7/abstract
Jacqueline French and Jacob Pellinen join Senior Editor Sarah Passey to discuss recent progress made in the diagnosis of epilepsy and challenges that remain. Their Review on this topic is published in the May issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00079-6/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
You've probably heard me say more than once that the things people affected by MS want most -- access to quality healthcare, affordable prescription medications, and funding for MS research -- are, to a large extent, all functions of public policy. The people who decide whether we get these things are our elected officials. That's why advocacy is so critically important. The National MS Society's Public Policy Conference gets underway on March 4th, and joining me with a preview of this year's conference is the MS Society's Vice-President of Advocacy, Steffany Stern. We're also taking a deep dive into a paper just published by a group of MS experts detailing the current status of progressive MS research, identifying lessons learned along the way, and calling out the remaining challenges to better understanding MS progression. We're sharing the details of how and where to register for this week's global webcast being hosted by the International Progressive MS Alliance. And I'm remembering my wife, Jeanne, on the fourth anniversary of her passing. We have a lot to talk about! Are you ready for RealTalk MS??! Jeanne's Story :22 This Week: Inside MS advocacy and this year's Public Policy Conference 8:36 Experts publish an update on progressive MS research, identify lessons learned, and call out the remaining challenges 9:35 The International Progressive MS Alliance hosts a global webcast this Thursday 17:22 MS Society's Vice-President of Advocacy, Steffany Stern, gives us a peek at this year's Public Policy Conference 18:54 Share this episode 31:51 Have you downloaded the free RealTalk MS app? 32:10 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/338 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society: Become an MS Activist https://nationalmssociety.org/advocacy PAPER: Clinical Trials for Progressive Multiple Sclerosis: Progress, New Lessons Learned, and Remaining Challenges https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(24)00027-9/abstract RealTalk MS Episode 280: How the Proposed Framework for Diagnosing and Treating MS Will Affect You with Dr. Tim Coetzee https://realtalkms.com/280 RealTalk MS Episode 193: Managing the Emotional Fallout of the Pandemic with Dr. Gayle Lewis https://realtalkms.com/193 WEBCAST: New Treatments for Progressive MS: Recent Advances and Promising Research https://www.msif.org/treatments-webcast/ Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 338 Guest: Steffany Stern Privacy Policy
Dr. Deanna Saylor and Prof. Mayowa Owolabi discuss reducing the global burden of stroke. Show reference: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00277-6/fulltext
Marianne Chapleau and Gil Rabinovici join Senior Editor Sarah Passey to discuss their research on posterior cortical atrophy. The Article is published in the February issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00414-3/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
The January 2024 replay starts the new year off with four previously posted episodes on dementia. The episode begins with an interview with Dr. Kenneth Langa on the prevalence of dementia and mild cognitive impairment in the US. The episode continues with an interview with Dr. Beau Ances about the burden amyloid has on individuals with Down syndrome compared to autosomal dominant Alzheimer disease. The next interview is with Dr. Erik Musiek on the use of lecanemab in early Alzheimer disease. The fourth and final interview is with Dr. Vijay Ramanan on the eligibility for anti-amyloid treatment. Related Podcast Links: Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the United States: https://directory.libsyn.com/episode/index/id/25811241 Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25881414 Lecanemab in Early Alzheimer Disease: https://directory.libsyn.com/episode/index/id/25428333 Eligibility for Anti-Amyloid Treatment: https://directory.libsyn.com/episode/index/id/28300052 Related Article Links: Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: https://jamanetwork.com/journals/jamaneurology/article-abstract/2797274?resultClick=1 Comparison of Amyloid Burden in Individuals with Down Syndrome Versus Autosomal Dominant Alzheimer's Disease: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00408-2/fulltext Eligibility for Anti-Amyloid Treatment in a Population-Based Study of Cognitive Aging: https://www.neurology.org/doi/10.1212/WNL.0000000000207770 Disclosures can be found at Neurology.org
Cecilia Åkerlund and David Nelson join The Lancet Neurology to discuss their research on clinical variables that might distinguish how the disease process progresses in people with traumatic brain injury. The Article is published in the January issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00358-7/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Rustam Al-Shahi Salman joins Senior Editor Sarah Passey to discuss the COCROACH meta-analysis findings, published in the December issue of The Lancet Neurology, of the effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00315-0/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Njideka Okubadejo and Mie Rizig join The Lancet Neurology to discuss their comprehensive genome-wide assessment in African and African admixed individuals with the aim of developing a better understanding of the genetic architecture of Parkinson's disease in these underserved populations.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00283-1/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
William Jagust (University of California in Berkeley, CA, USA) talks to Senior Editor Sarah Passey about the complex pathway between amyloid β and cognition, and implications for therapy for people with Alzheimer's disease. His Personal View on this topic is published in the September issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00128-X/fulltext?dgcid=buzzsprout_icw_podcast_generic_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
The ability to speak is something so basic to our day-to-day lives that you may not ever stop to consider it until you realize something about your speech may be changing. And swallowing is something that's so automatic, we take it for granted. Until, that is, something changes, and you find yourself choking on a sip of water. Speech and swallowing problems are fairly common MS symptoms. And joining me to discuss some of the most common speech and swallowing disorders people with MS might encounter, and how working with a speech pathologist can make a real difference in tackling those speech and swallowing issues is an internationally recognized medical Speech-Language Pathologist and Multiple Sclerosis Certified Specialist, Dr. Marissa Barrera. We're also sharing news about an updated guidance that's been published by a group of MS experts to help healthcare professionals avoid misdiagnosing MS. We'll tell you about results from a small study that demonstrate the potential risks associated with requiring prior authorization from insurance companies for disease-modifying therapies which have been prescribed to people newly diagnosed with MS. The International Progressive MS Alliance has published a report on the Scientific Congress it convened in June. We'll tell you where you can download your copy. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Improving speech and swallowing issues in MS :22 An international group of experts has published an updated guidance for neurologists and other healthcare professionals on how to distinguish MS from other neurological look-alikes 1:39 Results from a small study demonstrate that requiring prior authorization for disease-modifying therapies poses potential health risks for people newly diagnosed with MS 3:12 The International Progressive MS Alliance has published a report on the Scientific Congress it convened this past June 8:29 Dr. Marissa Barrera discusses some of the common speech and swallowing disorders people with MS might encounter 9:53 Share this episode 34:51 Have you downloaded the free RealTalk MS app? 35:10 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/309 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Differential Diagnosis of Multiple Sclerosis: An Updated Consensus Approach https://thelancet.com/journals/laneur/article/PIIS1474-4422(23)00148-5/fulltext STUDY: The Impact of Insurance Restrictions in Individuals Newly DIagnosed with Multiple Sclerosis https://meridian.allenpress.com/ijmsc/article/doi/10.7224/1537-2073.2022-069/494514/The-Impact-of-Insurance-Restrictions-in Report from the International Progressive MS Alliance 2023 Scientific Congress https://www.progressivemsalliance.org/wp-content/uploads/2023/07/230719-Alliance-Scientific-Congress-Report-July-2023.pdf RealTalk MS Episode 303: The International Progressive MS Alliance Scientific Congress (Part 1) https://realtalkms.com/303 RealTalk MS Episode 304: The International Progressive MS Alliance Scientific Congress (Part 2) https://realtalkms.com/304 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 309 Guest: Dr. Marissa Barrera Privacy Policy
Drs Nicholas Silvestri and James "Chip" Howard discuss newer and novel myasthenia gravis tools to personalize treatment, including complement inhibitors, FcRn antagonists, biomarkers, and more. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/990460). The topics and discussions are planned, produced, and reviewed independently of advertisers. This podcast is intended only for US healthcare professionals. Resources Safety and Efficacy of Eculizumab in Refractory Generalized Myasthenia Gravis (REGAIN Study) https://clinicaltrials.gov/ct2/show/NCT01997229 Safety and Efficacy of Eculizumab in Anti-acetylcholine Receptor Antibody-positive Refractory Generalised Myasthenia Gravis (REGAIN): A Phase 3, Randomised, Double-blind, Placebo-controlled, Multicentre Study https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(17)30369-1/fulltext ULTOMIRIS® (Ravulizumab-cwvz) Approved in the US for Adults With Generalized Myasthenia Gravis https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-approved-in-the-us-for-adults-with-generalized-myasthenia-gravis.html UCB Announces US FDA Acceptance of New Drug Application and EMA MAA Validation for Zilucoplan for the Treatment of Generalized Myasthenia Gravis in Adult Patients https://www.prnewswire.com/news-releases/ucb-announces-us-fda-acceptance-of-new-drug-application-and-ema-maa-validation-for-zilucoplan-for-the-treatment-of-generalized-myasthenia-gravis-in-adult-patients-301676223.html Zilucoplan: An Investigational Complement C5 Inhibitor for the Treatment of Acetylcholine Receptor Autoantibody–positive Generalized Myasthenia Gravis https://www.tandfonline.com/doi/full/10.1080/13543784.2021.1897567
In this episode Dr. Tiago Outeiro talks with Dr. Andrew Siderowf about the exciting new results in his most recent publication on alpha-synuclein seed amplification assay. Read the article.
The June 2023 replay of past episodes showcases a selection of interviews regarding the biomarker discovery in Parkinson disease. This episode begins with an overview of the latest in Parkinson's research, including biomarker development with Dr. Bas Bloom. The episode continues with an interview with Dr. Lucilla Parnetti about the clinical application of α-synuclein seed amplification, leading into an interview with Prof. Andrew Siderowf about seed amplification in PD in the PPMI cohort. The June Neurology Recall concludes with an interview with Dr. Christopher Gibbons on skin α-synuclein in MSA and PD. Related Links: Research in Movement Disorders in 2022: A New Era of Biomarker and Treatment Development: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00494-X/fulltex Podcast Link: https://directory.libsyn.com/episode/index/id/26775207 α-Synuclein Seed Amplification Assays for Diagnosing Synucleinopathies: The Way Forward: https://n.neurology.org/content/99/5/195 Podcast Link: https://directory.libsyn.com/episode/index/id/23923047 Assessment of Heterogeneity Among Participants in the Parkinson's Progression Markers Initiative Cohort Using α-Synuclein Seed Amplification: A Cross-Sectional Study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00109-6/fulltext Podcast Link: https://directory.libsyn.com/episode/index/id/26961315 Cutaneous α-Synuclein Signatures in Patients With Multiple System Atrophy and Parkinson Disease: https://n.neurology.org/content/100/15/e1529 Podcast Link: https://directory.libsyn.com/episode/index/id/26499948 For links to articles and previous podcast episodes, please visit NPUb.org/Podcast.
Prof. Andrew Siderowf discusses the assessment of heterogeneity among participants in the Parkinson progression markers initiative cohort using α-synuclein seed amplification. Show references: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00109-6/fulltext This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
On today's episode the guys discuss superstar actor Michael J Fox and the new documentary on his life, ‘Still' (0:52). The guys start off with the discussion with the story behind the “J” in Michael's name and his early life in British Colombia. They then discuss when they first encountered him in the NBC sitcom ‘Family Ties'. Asif and Ali then discuss Fox's breakthrough in ‘Back to the Future', as well as his other hit films. They then discuss his return to television with ‘Spin City' and how his diagnosis of Parkinson's disease at age 29 factored into this. They then discuss their thoughts on the new documentary on Fox's life ‘Still', directed by Davis Guggenheim. Then the guys discuss Parkinson's disease (27:02). Asif talks about what we know about the cause, the primary symptoms and how it is diagnosed. He then discusses the treatment how the the side effects from Parkinson's disease medications can cause their own problems. Asif then goes over surgery for Parkinson's, including deep brain stimulation. He then discuss a major scientific breakthrough in Parksonson's disease via research funded by the Michael J Fox Foundation. The opinions expressed are those of the hosts, and do not reflect those of any other organizations. This podcast and website represents the opinions of the hosts. The content here should not be taken as medical advice. The content here is for entertainment and informational purposes only, and because each person is so unique, please consult your healthcare professional for any medical questions. Music courtesy of Wataboi and 8er41 from Pixabay Contact us at doctorvcomedian@gmail.com Follow us on Social media: Twitter: @doctorvcomedian Instagram: doctorvcomedian Show Notes: Michael J. Fox Looks Back on Hollywood Triumphs, Setbacks and Why ‘Parkinson's Is the Gift That Keeps on Taking”: https://variety.com/2023/film/features/michael-j-fox-parkinsons-disease-still-documentary-1235607552/ Making a Michael J. Fox Movie With Michael J. Fox's Movies: https://www.nytimes.com/2023/05/14/movies/michael-j-fox-interview.html Billy Vera - At This Moment (HQ): https://www.youtube.com/watch?v=O2ur063fMhs Parkinson Disease: https://emedicine.medscape.com/article/1831191-overview Michael J. Fox, three co-workers at 70s TV show, all got Parkinson's: https://www.cbc.ca/news/canada/michael-j-fox-three-co-workers-at-70s-tv-show-all-got-parkinson-s-1.339756 Senate Appropriations Subcommittee on Labor, Health and Human Services, and Education Hearing on Parkinson's Research and Treatment September 28, 1999 The Testimony of Michael J. Fox: https://media.pluto.psy.uconn.edu/parkinsons/foxhearing.html The Michael J Fox Foundation: https://www.michaeljfox.org/ Breaking News: Parkinson's Disease Biomarker Found: https://www.michaeljfox.org/news/breaking-news-parkinsons-disease-biomarker-found?pn_cid=pn-a1b1R00000AlQ16 A Parkinson's ‘game changer,' backed by Michael J. Fox, could lead to new diagnostics and, someday, treatments: https://www.statnews.com/2023/04/12/michael-j-fox-parkinsons-biomarker/ Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(23)00109-6/fulltext
Andrew Cole (Massachusetts General Hospital Epilepsy Service, Boston, MA, USA) talks to Senior Editor Sarah Passey about the complexities underlying epilepsy in people with glioblastoma. His Review on this topic is published in the June issue of The Lancet Neurology.Read the full article here: thelancet.com/journals/laneur/article/PIIS1474-4422(23)00031-5/fulltext?dgcid=buzzsprout_icw_podcast_laneurContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Prof. Bastiaan Bloem discusses the latest developments in biomarkers and treatments for movement disorders, which have been described in numerous research papers from 2022. Show references: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00494-X/fulltext
Todo mundo tem algo que acha assustador, de filmes de terror a jogos macabros, passando por situações inesperadas.Mas como nosso cérebro e nosso corpo reagem a sustos? O que a ciência tem a dizer sobre isso?Confira o papo entre o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.> OUÇA (51min 17s)*Naruhodo! é o podcast pra quem tem fome de aprender. Ciência, senso comum, curiosidades, desafios e muito mais. Com o leigo curioso, Ken Fujioka, e o cientista PhD, Altay de Souza.Edição: Reginaldo Cursino.http://naruhodo.b9.com.br*PARCERIA: ALURAA Alura é a maior escola online de tecnologia e negócios digitais do Brasil.Com uma matricula você tem acesso as centenas de cursos online, com lançamentos e atualizações constantes nas áreas de programação, front-end, DevOps, Mobile, Data Science, UX & Design, Inovação e Gestão.E o melhor investimento que você pode fazer nesta Black Friday é no seu futuro.Sabe como?Aproveitando a chance única do maior desconto do ano na Alura: 25%, de 21 a 25 de novembro.Isso mesmo: 25% de desconto para aprofundar seus conhecimentos ou fazer a tão sonhada transição de carreira.Então aproveite a Black Friday Alura e chame suas amigas e seus amigos!Link: bit.ly/black-friday-alura-2022*REFERÊNCIASStartle Disease: New Molecular Insights into an Old Neurological Disorderhttps://journals.sagepub.com/doi/full/10.1177/10738584221104724Startle syndromeshttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(06)70470-7/fulltextMoro Reflex Newborn Test | Startle Reflex | Pediatric Nursing Assessmenthttps://www.youtube.com/watch?v=6AfkNg1i_LMHabituation of a startle responsehttps://www.youtube.com/watch?v=Kfu0FAAu-10Research Progress in the Study of Startle Reflex to Disease Stateshttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8884703/STARTLE DISEASE OR HYPEREKPLEXIA FURTHER DELINEATION OF THE SYNDROMEhttps://academic.oup.com/brain/article-abstract/103/4/985/360048?redirectedFrom=fulltext&login=falseThe glycinergic inhibitory synapsehttps://link.springer.com/article/10.1007/PL00000899Hyperekplexia and stiff-man syndrome: abnormal brainstem reflexes suggest a physiological relationshiphttps://jnnp.bmj.com/content/jnnp/75/9/1265.full.pdfELECTROCLINICAL FEATURES OF CONVULSIONS INDUCED BY STIMULATION OF BRAIN STEMhttps://journals.physiology.org/doi/abs/10.1152/jn.1958.21.5.430Startle syndromeshttps://www.sciencedirect.com/science/article/pii/S1474442206704707#fig1GLRB allelic variation associated with agoraphobic cognitions, increased startle response and fear network activation: a potential neurogenetic pathway to panic disorderhttps://www.nature.com/articles/mp20172The audiogenic startle response in Tourette's syndromhttps://movementdisorders.onlinelibrary.wiley.com/doi/abs/10.1002/mds.870100605Emotion modulation of the startle reflex in essential tremor: Blunted reactivity to unpleasant and pleasant pictureshttps://www.sciencedirect.com/science/article/pii/S1353802016304345?casa_token=a_uv0EAB-MAAAAAA:nVPXCMJIIN37x8BB_NeNa92WVKvWF3pu_TlOmOovfO1Lvd_JS0gVLXXRVCfObIp1ZIEkEA0KWosWhy twenty amino acid residue types suffice(d) to support all living systemshttps://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0204883Graph theory analysis of resting-state functional magnetic resonance imaging in essential tremorhttps://onlinelibrary.wiley.com/doi/abs/10.1002/hbm.24730?casa_token=ff_kOBj_o6sAAAAA:-8X5s4r8fdMGtMObacCBwEgMc4SYkOjoi18srOLSd2TGR4OexMfcoMPgwpCkG14LPdbhMxtYT18HClbjNaruhodo #173 - O que são cacoetes?https://www.youtube.com/watch?v=-Z3U2fqEYaINaruhodo #156 - O que é paralisia do sono?https://www.youtube.com/watch?v=h9om8soj_uA&t=465sNaruhodo #217 - Por que algumas pessoas tremem?https://www.youtube.com/watch?v=K7KLyBBnK_Q&t=12sNaruhodo #125 - Por que algumas pessoas passam mal ao ver sangue?https://www.youtube.com/watch?v=WS7GWadZ9lINaruhodo #309 - Por que sentimos medo? - Parte 1 de 2https://www.youtube.com/watch?v=xNwl26ZbVD8Naruhodo #310 - Por que sentimos medo? - Parte 2 de 2https://www.youtube.com/watch?v=cqkh5IdfQQMNaruhodo #164 - Podemos ler emoções com base em expressões faciais?https://www.youtube.com/watch?v=cq4oeBZ5kgo&t=4sNaruhodo #130 - Por que fazemos caretas quando executamos algumas tarefas?https://www.youtube.com/watch?v=XvGdV1lS7f8*APOIE O NARUHODO PELA PLATAFORMA ORELO!Um aviso importantíssimo: o podcast Naruhodo agora está no Orelo: https://bit.ly/naruhodo-no-oreloE é por meio dessa plataforma de apoio aos criadores de conteúdo que você ajuda o Naruhodo a se manter no ar.Você escolhe um valor de contribuição mensal e tem acesso a conteúdos exclusivos, conteúdos antecipados e vantagens especiais.Além disso, você pode ter acesso ao nosso grupo fechado no Telegram, e conversar comigo, com o Altay e com outros apoiadores.E não é só isso: toda vez que você ouvir ou fizer download de um episódio pelo Orelo, vai também estar pingando uns trocadinhos para o nosso projeto.Então, baixe agora mesmo o app Orelo no endereço Orelo.CC ou na sua loja de aplicativos e ajude a fortalecer o conhecimento científico.https://bit.ly/naruhodo-no-orelo
Spasticity is one of the most common symptoms of MS, impacting up to 80% of the people living with MS. It can feel like mild muscle tightness that you wish would just go away or it can be so painful and debilitating that it keeps you from moving. Dr. Michelle Cameron joins me in this episode to discuss what spasticity is and how to best manage it. Dr. Cameron is a neurologist and physical therapist, a professor in the Department of Neurology at Oregon Health & Science University, Interim Chief of Neurology at the VA Portland Healthcare System, and Co-Director of the VA MS Center of Excellence West. We're also talking about a new framework for thinking and talking about MS that's been proposed by an international panel of MS experts. We'll tell you about a study that looked at polypharmacy and MS (Of course, we'll also tell you what polypharmacy is and why you should be aware of it!) We'll share the details around the discovery of human antibodies that have been shown to prevent Epstein-Barr infection (And we'll explain why this could be incredibly important) If you're an MS caregiver, or you know one, I'm asking for just 5 minutes of your time. We're celebrating National Caregivers Month by breaking down the details of the National Family Caregiving Strategy that was recently submitted to Congress. And we're celebrating the indomitable quality of the human spirit by sharing the story of Eric Domingo Roldan and his mom, Sylvia. We have a lot to talk about! Are you ready for RealTalk MS??! Thanksgiving is two days away! :22 This Week: Managing Spasticity 1:02 Experts propose a new framework for thinking about and talking about MS 2:07 Polypharmacy and MS 5:55 Researchers identify antibodies that prevent Epstein-Barr Virus infection 9:02 If you're an MS caregiver, or you know one, can I have 5 minutes of your time? 11:30 The 2022 National Family Caregivig Strategy 13:55 Eric Domingo Roldan and his mom, Sylvia, make it into the Guinness Book of World Records 16:34 Dr. Michelle Cameron discusses spasticity and MS 18:40 Share this episode 33:55 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/273 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Multiple Sclerosis Progression: Time for a New Mechanism-Driven Frameworkhttps://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00289-7/fulltext Tremlett's MS Research Explained: Polypharmacy and Multiple Sclerosis: A Population-Based Study https://tremlettsmsresearchexplained.wordpress.com/2022/10/27/polypharmacy-and-multiple-sclerosis-a-population-based-study/ STUDY: Polypharmacy and Multiple Sclerosis: A Population-Based Study https://journals.sagepub.com/doi/full/10.1177/13524585221122207 RealTalk MS Episode 229: Evidence Shows MS Is Triggered by the Epstein-Barr Virus with Dr. Kassandra Munger and Dr. AJ Joshi https://realtalkms.com/229 RealTalk MS Episode 231: Evidence Shows EBV Triggers MS: Understanding the Impact of this Breakthrough Research with Dr. Bruce Bebo https://realtalkms.com/231 STUDY: Epstein-Barr Virus gH/gL Has Multiple Sites of Vulnerability for Virus Neutralization and Fusion Inhibition https://cell.com/immunity/fulltext/S1074-7613(22)00544-1 Take the iConquer MS Caregiver Survey https://realtalkms.com/caregiver 2022 National Strategy to Support Family Caregivers https://acl.gov/sites/default/files/RAISE_SGRG/NatlStrategyToSupportFamilyCaregivers.pdf Eric Domingo Roldan's Instagram Handle @eeRiicbcn Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 273 Guest: Dr. Michelle Cameron Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy
Dr. Tissa Wijeratne discusses strategic initiatives to reduce the burden of migraine. Show references: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00295-2/fulltext This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
Dr. Tissa Wijeratne discusses the global burden of migraine. Show references: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00295-2/fulltext This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
Dr. Tissa Wijeratne discusses his article, "Brain health for all on World Brain Day 2022". Show references: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00295-2/fulltext This podcast is sponsored by argenx. Visit www.vyvgarthcp.com for more information.
Vidcast: https://youtu.be/lnfpbeZ7pqU Victims of Traumatic Brain Injuries, TBI for short, have a 23 to 63 fold higher risk of death during the ensuing 6 months when they have high levels of two protein biomarkers circulating in their bloodstreams on the day of injury. This conclusion stems from a collaborative study from the University of Michigan, UC-San Francisco, and the University of Pennsylvania. The researchers studied 1700 patients with TBI and measured their circulating levels of two proteins, GFAP and UCH-L1 as they were admitted to the hospital. The levels of these proteins were compared with the occurrence of patient mortality within 6 months post-injury. Those with the highest vs. the lowest GFAP values had a 23 times higher risk of death while those with the highest vs. the lowest UCH-L1 values had a 63 times higher risk of death. This prospective data is invaluable for setting realistic family expectations for patient recovery after these devastating episodes of head trauma. https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00256-3/fulltext #tbi #gfap #uchl1 #mortality tbi, gfap, uchl1, mortality
Dr. Sabeen Dhand talks with Neurointerventionalist Dr. Ansaar Rai from about his approach to posterior circulation strokes, including patient selection, technique and devices, and pitfalls to avoid. --- CHECK OUT OUR SPONSOR CERENOVUS https://www.jnjmedicaldevices.com/en-US/companies/cerenovus --- SHOW NOTES In this episode, neurointerventional radiologist Dr. Ansaar Rai joins Dr. Sabeen Dhand to discuss posterior circulation stroke, including when to treat with thrombectomy, techniques, and advances in stroke research in recent years. They discuss factors to consider when deciding to treat posterior circulation strokes with thrombectomy. Dr. Rai reports that age is the most important factor, followed by comorbidities and severity of clinical symptoms. He discusses the variability in presentation of basilar artery strokes, ranging from mild ataxia to coma. He treats these aggressively with thrombectomy, especially for young patients. For isolated PCA strokes, he often treats with intra arterial TPA only. Dr. Rai next discusses landmark clinical trials, as well as his own research looking at stroke burden. He found that 2% of all acute ischemic strokes occur in the posterior circulation. Importantly, he postulates that there will never be good posterior circulation trials due to lack of equipoise and difficulty in randomizing to a medical treatment only arm. Dr. Rai uses general anesthesia for posterior circulation strokes. He prefers femoral access, and uses an 8Fr femoral short sheath and a guide catheter (ideally 088), rather than a balloon guide catheter. He then uses an 070 or 072 intermediate aspiration catheter navigated over an 024 microwire (Aristotle) or 027 microcatheter (Duo or XT-27) into the basilar. After trying many techniques, he prefers aspiration using the ADAPT technique. If he has to cross clot, he uses a stent retriever such as Trevo, Embotrap or Solitaire. Due to the delicate vasculature and high risk in posterior circulation thrombectomies, Dr. Rai always uses a J wire, biplane imaging and emphasizes that knowing the anatomy on CT is key to decreasing complications such as dissection or distal embolization. --- RESOURCES ASPECTS score: https://www.ahajournals.org/doi/10.1161/STROKEAHA.117.016745 Route 92 Medical SUMMIT MAX Clinical trial: https://evtoday.com/news/route-92-medicals-monopoint-reperfusion-system-studied-in-pivotal-summit-max-trial#:~:text=According%20to%20Route%2092%20Medical%2C%20SUMMIT%20MAX%20is,sites%20in%20the%20United%20States%20and%20New%20Zealand. The Greater Cincinnati Northern Kentucky Stroke Study: https://www.gcnkss.com MR RESUE trial: https://www.ahajournals.org/doi/full/10.1161/strokeaha.113.001443 IMS3 trial: https://evtoday.com/news/ims-3-substudy-shows-delays-in-stroke-treatment-leads-to-worse-outcomes#:~:text=IMS%203%20was%20a%20multicenter%20international%20trial%20in,received%20tPA%20within%203%20hours%20of%20stroke%20onset. SWIFT PRIME trial: https://evtoday.com/news/covidien-commences-enrollment-for-swift-prime-acute-ischemic-stroke-study#:~:text=The%20SWIFT%20PRIME%20study%20will%20evaluate%20acute%20ischemic,will%20also%20include%20an%20extensive%20health%20economics%20analysis. ADAPT technique trial by Turc: https://www.ahajournals.org/doi/10.1161/STROKEAHA.119.025753 BEST trial: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30395-3/fulltext#:~:text=The%20BEST%20trial%20was%20a%20multicentre%2C%20prospective%2C%20open-label%2C,the%20institutional%20review%20board%20of%20each%20participating%20site. ATTENTION trial: https://pubmed.ncbi.nlm.nih.gov/35102797/
Read Paediatric Neurologist, Clinician-Scientist, Laureate Professor Ingrid Scheffer, AO's piece in the Lancet Neurology: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00002-3/fulltext Here is the quote Mike read: “It will not be feasible to design a gene therapy for each pathogenic variant of every genetic disease, so clever strategies, such as those mentioned earlier, will need to be developed to enable these life-changing therapies to reach a wide variety of patients. The future of child neurology is bright—indeed, far more promising than at the turn of the 21st century. Many devastating diseases now have real hope of targeted therapies, which can cure not just one but all manifestations of the disease and offer the child and family the promise of a normal life.” SRF article on IPSCs: https://www.syngapresearchfund.org/post/another-srf-contribution-to-syngap1-research-patient-derived-cell-lines-to-test-treatments SRF article on reading your genetic report: https://www.syngapresearchfund.org/post/understanding-your-genetic-report-with-syngap1-a-rare-disease SRF article on VUS: https://www.syngapresearchfund.org/post/does-your-genetic-report-contain-a-variant-of-unknown-significance-vus-in-syngap1 REMEMBER Raise funds at https://syngap.fund/give Subscribe to and rate this 10 minute #podcast #SYNGAP10 here https://syngap.fund/10 if you want a direct link for Apple: https://syngap.fund/10a Episode 44 of #Syngap10 - January 21, 2022 #missense #SYNGAP1 #F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #Genetics --- Send in a voice message: https://podcasters.spotify.com/pod/show/syngap10/message
Read Paediatric Neurologist, Clinician-Scientist, Laureate Professor Ingrid Scheffer, AO's piece in the Lancet Neurology: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(22)00002-3/fulltext Here is the quote Mike read: “It will not be feasible to design a gene therapy for each pathogenic variant of every genetic disease, so clever strategies, such as those mentioned earlier, will need to be developed to enable these life-changing therapies to reach a wide variety of patients. The future of child neurology is bright—indeed, far more promising than at the turn of the 21st century. Many devastating diseases now have real hope of targeted therapies, which can cure not just one but all manifestations of the disease and offer the child and family the promise of a normal life.” SRF article on IPSCs: https://www.syngapresearchfund.org/post/another-srf-contribution-to-syngap1-research-patient-derived-cell-lines-to-test-treatments SRF article on reading your genetic report: https://www.syngapresearchfund.org/post/understanding-your-genetic-report-with-syngap1-a-rare-disease SRF article on VUS: https://www.syngapresearchfund.org/post/does-your-genetic-report-contain-a-variant-of-unknown-significance-vus-in-syngap1 REMEMBER Raise funds at https://syngap.fund/give Subscribe to and rate this 10 minute #podcast #SYNGAP10 here https://syngap.fund/10 if you want a direct link for Apple: https://syngap.fund/10a Episode 44 of #Syngap10 - January 21, 2022 #missense #SYNGAP1 #F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #Genetics
Alberto Costa (Case Western Reserve University, Cleveland, OH, USA) discusses his study on the use of memantine in adolescents and young adults with Down syndrome, which is published in the January issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00369-0/fulltext
Olivier Rascol (Toulouse University, France) discusses the uses of amantadine in the treatment of patients with movement disorders, which are the focus of his Personal View in the December issue of The Lancet Neurology.Read the full article:https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00249-0/fulltext
Kontakt: ivajuntan@gmail.com Musik: Blind Love Dub by Jeris (c) copyright 2017 Licensed under a Creative Commons Attribution (3.0) license. http://dig.ccmixter.org/files/VJ_Memes/55416 Ft: Kara Square (mindmapthat) Länk till UNICEFs stoppa COVID-19-paket Dagens artiklar: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00138-1/fulltext https://pubmed.ncbi.nlm.nih.gov/32934100/ Om du gillar du det vi gör - stöd Life Support Foundation! www.lifesupportfoundation.org Bli månadsgivare eller använd Swish: 1234610804 Länk till Critical Care Reviews: https://criticalcarereviews.com See omnystudio.com/listener for privacy information.
Kontakt: ivajuntan@gmail.com Musik: Blind Love Dub by Jeris (c) copyright 2017 Licensed under a Creative Commons Attribution (3.0) license. http://dig.ccmixter.org/files/VJ_Memes/55416 Ft: Kara Square (mindmapthat) Länk till UNICEFs stoppa COVID-19-paket Dagens artikel: https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(21)00138-1/fulltext Om du gillar du det vi gör - stöd Life Support Foundation! www.lifesupportfoundation.org Bli månadsgivare eller använd Swish: 1234610804 Länk till Critical Care Reviews: https://criticalcarereviews.com See omnystudio.com/listener for privacy information.
One of the top killers of people over the age of 65, Alzheimer's Disease is the target of cutting edge pharmaceutical research and basic science. What do we already know about the symptoms and their biological causes? As it turns out, there is still a good amount of controversy when it comes to the fundamental mechanism of this disease! Ad Link: https://omio.sjv.io/c/2544961/1078765/7385 References: https://www.nia.nih.gov/health/alzheimers-disease-fact-sheet https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181715/ https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(18)30403-4/fulltext https://www.cdc.gov/aging/aginginfo/alzheimers.htm https://www.mayoclinic.org/diseases-conditions/alzheimers-disease/symptoms-causes/syc-20350447 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3174086/ https://www.nature.com/articles/s41598-019-44848-2 https://link.springer.com/chapter/10.1007/978-3-319-72938-1_3 https://www.hopkinsmedicine.org/health/conditions-and-diseases/alzheimers-disease/earlyonset-alzheimer-disease https://www.jneurosci.org/content/34/38/12893 https://www.nature.com/articles/s41598-018-37476-9 https://link.springer.com/article/10.1007/s00109-016-1427-y https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3042623/ https://www.frontiersin.org/articles/10.3389/fnins.2018.00025/full?mod=article_inline
Para este tercer y último episodio dedicado al congreso mundial de neurorrehabilitación, me voy a valer de dos ponencias que en realidad voy a mezclar ya que el contenido de una está dentro de la otra. Esta unión la hago a propósito de hablar de los BCIs y el papel que están jugando en la investigación y poco a poco en la clínica. Las dos ponencias en cuestión son la de Surjo Soekadar sobre si estamos preparados para los BCIs y la de Edeny Baaklini sobre la estimulación eléctrica epidural. Referencias del episodio: (1). Daly (2008). Brain–computer interfaces in neurological rehabilitation (https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(08)70223-0/fulltext). (2). Benabid (2019). An exoskeleton controlled by an epidural wireless brain–machine interface in a tetraplegic patient: a proof-of-concept demonstration (https://www.thelancet.com/journals/laneur/article/PIIS1474-4422(19)30321-7/fulltext?utm_campaign=TLNExoSkelVid&utm_source=youtube&utm_medium=social). (3). Soekadar (2015). Brain–machine interfaces in neurorehabilitation of stroke (https://www.sciencedirect.com/science/article/pii/S0969996114003714#f0005). (4). Soekadar (2016). Hybrid EEG/EOG-based brain/neural hand exoskeleton restores fully independent daily living activities after quadriplegia (https://robotics.sciencemag.org/content/1/1/eaag3296/tab-pdf). (5). Ramos-Murguialday (2013). Brain–machine interface in chronic stroke rehabilitation: A controlled study (https://onlinelibrary.wiley.com/doi/abs/10.1002/ana.23879). (6). Donati (2016). Long-Term Training with a Brain-Machine Interface-Based Gait Protocol Induces Partial Neurological Recovery in Paraplegic Patients (https://www.nature.com/articles/srep30383#Sec6). (7). Wagner (2018). Targeted neurotechnology restores walking in humans with spinal cord injury (https://www.nature.com/articles/s41586-018-0649-2#additional-information). (8). Coscia (2019). Neurotechnology-aided interventions for upper limb motor rehabilitation in severe chronic stroke (https://academic.oup.com/brain/article/142/8/2182/5524504).